Key Points
New Delhi:The Goods and Services Tax (GST) Council announced slashing tax rates on three key anti-cancer drugs from 12 to 5 percent on Monday.The.
The anti-cancer medicines on which the government has offered BCD concession and now GST reduction include immune and targeted therapies such as trastuzumab deruxtecan, osimertinib, and durvalumaball three by British-Swedish pharma giant AstraZeneca...
However, top oncologists said that the majority of the new drugs continue to be out of reach for the vast majority of cancer patients due to high costs...
The reduction in GST from 12 to 5 percent for (some) cancer medicines is a welcome move that will to some extent, at least make these drugs more affordable and accessible, Dr C.S. Pramesh, the director of the Tata Memorial Hospital and the professor and head of thoracic surgery at the hospital, told ThePrint...
Many of the new cancer drugs are out of reach for the vast majority of cancer patients in India because of the high coststhe pharmaceutical industry needs to look at some innovative solutions so that these effective drugs reach the people they will benefit...
